2 completed, 2 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Dominant Dystrophic Epidermolysis Bullosa: new trials by email Literature Review of Dominant Dystrophic Epidermolysis Bullosa trials Research Report on Dominant Dystrophic Epidermolysis Bullosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Open Label Topical Beremagene Geperpavec (B-VEC) - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 47 | 2021-05-25 | 2024-04-09 |
| Long-Term Follow-up Protocol Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Recruiting | Krystal Biotech, Inc. | 50 | 2021-05-25 | 2021-06-08 | |
| Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Topical Beremagene Geperpavec, Placebo - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 31 | 2020-08-17 | 2023-02-17 |
Epidermolysis Bullosa Dystrophica (4) · Corneal Injuries (1)
Collagen Diseases (4) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Connective Tissue Diseases (4) · Epidermolysis Bullosa (4) · Genetic Diseases, Inborn (4) · Skin Abnormalities (4) · Skin Diseases (4) · Skin Diseases, Genetic (4) · Skin Diseases, Vesiculobullous (4) · Skin and Connective Tissue Diseases (4) · Corneal Diseases (1) · Craniocerebral Trauma (1) · Eye Diseases (1) · Eye Injuries (1)
United States (4)
David Chien, MD (1)